Competing/conflicts of interest: No stated conflict of interest.
Angle closure and angle-closure glaucoma: what we are doing now and what we will be doing in the future
Version of Record online: 5 APR 2012
© 2012 The Authors. Clinical and Experimental Ophthalmology © 2012 Royal Australian and New Zealand College of Ophthalmologists
Clinical & Experimental Ophthalmology
Volume 40, Issue 4, pages 381–387, May/June 2012
How to Cite
Friedman, D. S., Foster, P. J., Aung, T. and He, M. (2012), Angle closure and angle-closure glaucoma: what we are doing now and what we will be doing in the future. Clinical & Experimental Ophthalmology, 40: 381–387. doi: 10.1111/j.1442-9071.2012.02774.x
Funding sources: No stated funding sources.
- Issue online: 14 JUN 2012
- Version of Record online: 5 APR 2012
- Accepted manuscript online: 22 FEB 2012 07:43AM EST
- Received 7 February 2012; accepted 8 February 2012.
- angle-closure glaucoma;
- clinical trial;
Primary angle-closure glaucoma (PACG) frequently leads to severe vision loss. Prevalence among older Asian populations is high and given global demographics, the number of persons with PACG will increase dramatically in the coming decades. Improvements in imaging of the anterior segment will help us to identify more of those with angle closure, and important clinical trials that are currently underway will provide important evidence to support screening and treatment approaches for PACG. In this manuscript, we intend to review the existing evidences, to introduce some important on-going studies on PACG and to share the experience and viewpoints of the authors.